10:41 AM EDT, 10/22/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Tuesday it has achieved preclinical proof of concept for in vivo gene editing of hematopoietic stem cells in humanized mice to support the treatment of blood disorders like sickle cell disease and beta-thalassemia.

The company also said it is exploring options to partner or out-license its reni-cel program, a cell therapy for sickle cell disease and beta-thalassemia, to reduce future costs and support further development.

Price: 3.56, Change: -0.21, Percent Change: -5.45